Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Zappasodi R, et al. Among authors: hirschhorn cymerman d. Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. Cancer Cell. 2018. PMID: 29894689 Free PMC article.
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Zappasodi R, et al. Among authors: hirschhorn cymerman d. Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. Cancer Cell. 2018. PMID: 30300585 Free PMC article. No abstract available.
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Lesokhin AM, et al. Among authors: hirschhorn cymerman d. Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15. Cancer Res. 2012. PMID: 22174368 Free PMC article.
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. Khalil DN, et al. Among authors: hirschhorn cymerman d. Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Adv Cancer Res. 2015. PMID: 26216629 Review.
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, Merghoub T. Avogadri F, et al. Among authors: hirschhorn cymerman d. Cancer Immunol Res. 2014 May;2(5):448-58. doi: 10.1158/2326-6066.CIR-13-0220. Epub 2014 Feb 26. Cancer Immunol Res. 2014. PMID: 24795357 Free PMC article.
18 results